AC Immune (NASDAQ:ACIU) Releases Earnings Results, Misses Estimates By $0.05 EPS

Key Points

• AC Immune reported a quarterly EPS of ($0.25), which missed the consensus estimate of ($0.18) by ($0.07).
• The company has a negative return on equity of 44.60% and a negative net margin of 177.79%.
• Brokerages have reacted by upgrading AC Immune's rating to "buy," although HC Wainwright reduced its target price from $16.00 to $12.00.

AC Immune (NASDAQ:ACIU - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05), Zacks reports. The company had revenue of $1.65 million during the quarter, compared to the consensus estimate of $1.98 million. AC Immune had a negative return on equity of 45.76% and a negative net margin of 174.94%.

AC Immune Price Performance

Shares of ACIU stock opened at $2.17 on Thursday. The stock has a market cap of $217.89 million, a P/E ratio of -3.74 and a beta of 1.65. The company has a fifty day moving average price of $2.06 and a two-hundred day moving average price of $2.07. AC Immune has a one year low of $1.43 and a one year high of $3.98.

Institutional Investors Weigh In On AC Immune

A hedge fund recently raised its stake in AC Immune stock. Acadian Asset Management LLC boosted its position in AC Immune (NASDAQ:ACIU - Free Report) by 87.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 371,177 shares of the company's stock after purchasing an additional 172,796 shares during the quarter. Acadian Asset Management LLC owned about 0.37% of AC Immune worth $679,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 51.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright cut their price objective on shares of AC Immune from $16.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Wall Street Zen raised AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.